18

Cancer Rop Co. Ltd.

180400 · KQ · Healthcare / Diagnostics & Research

2,065.00KRW-10.00 (-0.48%)

Price History

Full chart

Market Stats

Previous Close2,075.00
Open2,085.00
Day Range1,950.00 – 2,135.00
52-Week Range1,319.00 – 5,360.00
Volume58.31K
Market Cap226.88B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.00
50-Day Avg2,435.76
200-Day Avg3,336.32

About

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs. Its pipeline includes Vx product, oral pediatric Covid19/influenza vaccine; new anti-cancer antibody drug; an antibody drug utilizing advanced mRNA vaccine development technique; Vx Microbiome R&D pipeline, a bacterial vaccine against respiratory diseases, new drugs targeting obesity and diagnosis etc; and Oxford Vacmedix Vaccine, an anti-cancer vaccineutilizing ROP technology. It has a research collaboration with bereum, Bioapp, CORESTEMCHEMON, Genscript PROBIO, JOINTOWN PHARMACEUTICAL GROUP,etc. The company was formerly known as Cancer Rop Co., Ltd. and changed its name to Dx & Vx Co., Ltd. in January 2022. The company was founded in 2001 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Yong-Gu Lee
  • Employees0
  • HeadquartersElysia Building 173, Seoul, South Korea, Korea
  • Websitehttps://www.dxvx.com

Leadership

  • Mr. Yong-Gu LeeChief Executive Officer
  • Mr. Kyu-chan KwonPresident · b. 1970
  • Mr. Chi-woo AnVP & CFO
  • Mr. Sungjun HanChief Technology Officer · b. 1969
  • Mr. Sang-Jin Park M.B.A., Ph.D.Head of R&D and Director · b. 1971
  • Kyu-hang Lee Ph.D.Head of New Drug Development
  • Mr. Won-Jin LeeHead of Invitro Diagnostics
  • Mr. Geon-Sang YooVP & Head of Management BU

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.69B5.39B5.10B4.67B7.51B32.18B41.24B33.95B29.36B
Growth (%)-+14.85%-5.38%-8.38%+60.82%+328.51%+28.15%-17.69%-13.52%
Cost of Revenue2.79B2.71B3.13B4.00B6.38B22.12B33.67B28.81B26.04B
Gross Profit1.90B2.67B1.96B672.32M1.13B10.06B7.58B5.14B3.32B
Gross Margin40.44%49.61%38.51%14.40%15.07%31.27%18.37%15.14%11.31%
Operating Expense1.52B2.11B2.64B3.93B6.22B7.43B23.02B26.74B27.64B
Operating Income373.00M561.38M-681.66M-3.25B-5.09B2.63B-15.45B-21.60B-24.32B
Operating Margin7.95%10.42%-13.37%-69.68%-67.71%8.18%-37.46%-63.63%-82.85%
EBITDA------44.78M-22.51B-49.34B-27.47B
EBITDA Margin------0.14%-54.58%-145.35%-93.57%
Net Income208.08M615.40M-479.52M-2.18B-5.37B-779.65M-27.48B-47.03B-29.04B
Net Income Margin4.44%11.42%-9.41%-46.64%-71.44%-2.42%-66.63%-138.55%-98.92%
R&D167.06M360.87M598.62M614.57M757.47M791.53M3.33B10.28B8.63B
R&D as % of Total Revenue3.56%6.70%11.74%13.16%10.09%2.46%8.08%30.28%29.38%
Interest Expense000001.44B5.44B4.80B2.80B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%4.47%13.20%14.15%9.54%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.70B22.17B29.70B57.23B67.54B85.95B99.94B72.36B154.87B
Total Liabilities522.87M614.80M644.52M22.49B32.64B51.60B71.14B56.00B59.11B
Total Equity7.18B21.56B29.05B34.75B34.91B33.97B21.17B13.97B93.95B
Cash2.45B3.83B10.09B36.83B7.84B25.29B7.53B9.61B103.43B
Net Debt-----9.30B31.41B32.46B-

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow783.83M-841.17M-1.50B-2.14B-4.94B865.55M-12.06B-20.03B-18.85B
Investing Cash Flow-312.01M-11.51B-259.86M-1.65B-34.59B----
Financing Cash Flow13.73B13.73B8.02B30.53B10.55B----
Capital Expenditure316.72M237.42M480.56M1.95B4.17B1.74B2.18B833.90M1.41B
Free Cash Flow------873.01M-14.25B-20.86B-20.27B
FCF to OCF------100.86%118.11%104.16%107.50%

Key Statistics & Ratios

Market Cap226.88B
Enterprise Value199.45B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.65
Price / Book2.85
Revenue (TTM)26.22B
Gross Profit (TTM)1.68B
EBITDA-18.89B
Profit Margin-96.17%
Operating Margin-94.24%
Return on Equity-58.35%
Return on Assets-15.00%
Shares Outstanding98.43M
Shares Float33.00M
Beta0.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%